Welcome to our dedicated page for Inovio Pharmaceuticals news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceuticals stock.
Inovio Pharmaceuticals reports developments in DNA medicines for HPV-related diseases, cancer and infectious diseases. Its updates center on INO-3107, a DNA immunotherapy candidate for recurrent respiratory papillomatosis, including clinical data, scientific publications, FDA review milestones and presentations at medical and biotechnology conferences.
Company news also includes quarterly and annual financial results, business updates, research on DNA-encoded monoclonal antibodies and DNA-encoded protein technology, collaboration activity and capital-structure actions involving common stock, warrants and at-the-market financing programs.
INOVIO (NASDAQ: INO) announced participation in two investor events in New York. The company will join the Cantor Global Healthcare Conference on Wednesday, September 9, featuring a fireside chat at 3:20 PM ET with a live webcast. INOVIO will also present at the H.C. Wainwright 28th Annual Global Investment Conference, with a virtual presentation available starting Friday, September 11 at 7:00 AM ET. Webcast and virtual links will host replays for 90 days, and management plans to hold one-on-one meetings with investors during both conferences.
Inovio (NASDAQ: INO) reported second quarter 2026 results and pipeline progress. The FDA review of its BLA for INO-3107 in recurrent respiratory papillomatosis is advancing under the accelerated approval program, with a PDUFA target date of October 30, 2026, following a late-cycle meeting and completion of all scheduled pre-licensure inspections. Inovio is preparing U.S. commercial launch infrastructure and has engaged Syneos Health for MSLs and contract sales support.
Partner ApolloBio’s pivotal Phase 3 trial of VGX-3100 in cervical dysplasia met its primary efficacy endpoint with favorable safety in China. Q2 2026 R&D and G&A expenses fell to $10.8 million and $7.8 million, respectively, reducing total operating expenses to $18.6 million. Net loss narrowed to $6.0 million versus $23.5 million a year earlier, mainly from a $13.9 million non-cash warrant liability gain. Cash, cash equivalents and short-term investments were $36.7 million at June 30, 2026, excluding $18.3 million in net proceeds from a July equity offering, and are expected to fund operations into late Q1 2027, including a potential INO-3107 launch, if approved.
INOVIO (NASDAQ: INO) will release its second quarter 2026 financial results after the market close on August 12, 2026. The company will host a live, listen-only conference call and webcast at 4:30 p.m. ET to review the results and provide a general business update. The webcast, including a live Q&A with analysts, will be accessible via INOVIO's investor relations website and will remain available as an archived replay for 90 days.
INOVIO (Nasdaq: INO) priced an underwritten public offering of 21,052,632 common shares and accompanying warrants to purchase up to 42,105,264 shares (or pre-funded warrants) at a combined public price of $0.95 per share and two warrants, with a warrant exercise price of $1.10 per share.
According to INOVIO, the underwriter has a 30-day option to buy up to 3,157,894 additional shares and/or warrants to purchase 6,315,788 shares. All securities are being sold by the company, which expects gross proceeds of approximately $20.0 million before fees, with closing anticipated around July 31, 2026. Piper Sandler is sole manager.
Inovio (Nasdaq: INO) announced a proposed underwritten public offering of common stock and accompanying warrants to purchase common stock, or pre-funded warrants in lieu of common stock. Inovio intends to grant the underwriter a 30-day option to buy up to an additional 15% of the offered shares and/or accompanying warrants on the same terms.
All securities in the proposed offering would be sold by Inovio. The transaction is subject to market conditions, with no assurance on completion, size, or terms. Piper Sandler is acting as sole manager. The securities are being offered under an effective shelf registration statement filed July 2, 2026 and declared effective July 10, 2026.
INOVIO (NASDAQ: INO) announced participation in upcoming scientific and investor conferences. Management will take part in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4 at 8:45 AM ET and present a poster at the World Orphan Drug Congress in Boston on June 11 from 12:00–12:10 PM ET.
A replay of the Jefferies investor event will be available for 90 days, and management will also hold one-on-one meetings with investors.
INOVIO (NASDAQ: INO) reported that partner ApolloBio announced positive topline results from a pivotal Phase 3 trial of VGX-3100 in cervical dysplasia patients. The study met its predefined primary efficacy endpoint and showed an overall favorable safety and tolerability profile, supporting a planned regulatory submission in China.
Under the ApolloBio agreement, INOVIO may receive up to $20 million in regulatory milestones, net of taxes, plus tiered royalties on annual net sales if VGX-3100 is approved and marketed in specified territories.
INOVIO (NASDAQ: INO) reported Q1 2026 results and pipeline updates. R&D expenses were $14.1M, G&A $7.9M and total operating expenses $21.9M, all lower year over year. Net loss was $19.7M, or $0.28 per share. Cash and investments were $37.7M, excluding $16.0M April offering proceeds.
The FDA is actively reviewing the BLA for INO-3107 for recurrent respiratory papillomatosis, with an accelerated approval target PDUFA date of October 30, 2026. INOVIO plans U.S. self-commercialization and expects current cash to fund operations into Q1 2027. The company also announced an INO-5412 GBM trial collaboration with Akeso.
INOVIO (NASDAQ:INO) will present posters at two upcoming scientific conferences in May 2026: the American Society of Gene and Cell Therapy (Boston) and the American Society of Clinical Oncology (Chicago). Presentations cover hemophilia A gene transfer and INO-3107 DNA immunotherapy for recurrent respiratory papillomatosis. Available abstracts will be posted on the company website after each presentation.
INOVIO (NASDAQ:INO) will release its first quarter 2026 financial results after market close on May 13, 2026. A live conference call and webcast will follow at 4:30 p.m. ET for a financial review and general business update, with a listen-only format and live Q&A.
The webcast will be archived and available for replay for 90 days at the company's investor events page.